Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo plus Ipi): Results from the International mRCC Database Consortium (IMDC).

被引：0
|
作者：
Lemelin, Audreylie
Takemura, Kosuke
Ernst, Matthew Scott
Wells, J. Connor
Donskov, Frede
Porta, Camillo
de Velasco, Guillermo
Davis, Ian D.
Wood, Lori
Pal, Sumanta Kumar
Hansen, Aaron Richard
Kollmannsberger, Christian K.
Bjarnason, Georg A.
Tran, Ben
Li, Haoran
Kanesvaran, Ravindran
Powles, Thomas
McKay, Rana R.
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] BC Canc Agcy, Vancouver, BC, Canada
[3] Univ Hosp Southern Denmark, Esbjerg, Denmark
[4] Univ Bari, Bari, Italy
[5] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[6] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia
[7] Eastern Hlth, Melbourne, Vic, Australia
[8] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[9] City Hope Natl Med Ctr, Duarte, CA USA
[10] Univ Toronto, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] Univ British Columbia, Dept Med, British Columbia Canc Agcy, Vancouver, BC, Canada
[12] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[13] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[14] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[15] Natl Canc Ctr Singapore, Singapore, Singapore
[16] Queen Mary Univ London, Barts Canc Inst, London, England
[17] Univ Calif San Diego Hlth, Moores Canc Ctr, San Diego, CA USA
[18] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4538
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Gan, Chun Loo
    Wells, J. Connor
    Schmidt, Andrew Lachlan
    Powles, Thomas
    Tran, Ben
    Meza, Luis A.
    Labaki, Chris
    Lee, Jae-Lyun
    Wood, Lori
    Shapiro, Julia
    Ernst, D. Scott
    Kapoor, Anil
    Canil, Christina M.
    Yuasa, Takeshi
    McKay, Rana R.
    Beuselinck, Benoit
    Donskov, Frede
    Dudani, Shaan
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
    Ferrier, Evan
    Lemelin, Audreylie
    Powles, Thomas
    Pal, Sumanta Kumar
    Ebrahimi, Hedyeh
    Agarwal, Neeraj
    Beuselinck, Benoit
    Bjarnason, Georg A.
    Wood, Lori
    Canil, Christina M.
    Saliby, Renee Maria
    de Velasco, Guillermo
    Mckay, Rana R.
    Tran, Ben
    Suarez, Cristina
    Templeton, Arnoud J.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 395 - 395
  • [3] Third line therapy in metastatic renal cell carcinoma (mRCC): results from the international mRCC database consortium (IMDC)
    Stukalina, Igor
    Wellsa, J. Connor
    Donskovb, Frede
    Rinic, Brian I.
    Leed, Jae-Lyun
    Bjarnasone, Georg A.
    Beuselinckf, Benoit
    Smoragiewicz, Martin
    Alvah, Ajjai Shivaram
    Srinivasi, Sandy
    Woodi, Lori
    Saleemk, Sadia
    Pal, Sumanta Kumar
    Yuasam, Takeshi
    Broomn, Reuben James
    Kanesvaran, Ravindran
    Bamiasp, Aristotelis
    Knoxq, Jennifer J.
    Henga, Daniel Y. C.
    Choueirir, Toni K.
    [J]. BJU INTERNATIONAL, 2015, 116 : 21 - 21
  • [4] Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
    Gul, Anita
    Shah, Neil J.
    Mantia, Charlene
    Hammers, Hans J.
    Ornstein, Moshe Chaim
    McDermott, David F.
    Atkins, Michael B.
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Heng, Daniel Yick Chin
    Stukalin, Igor
    Wells, Connor
    Donskov, Frede
    Rini, Brian I.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Smoragiewicz, Martin
    Alva, Ajjai Shivaram
    Srinivas, Sandy
    Wood, Lori
    Brugarolas, James
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Broom, Reuben James
    Kanesvaran, Ravindran
    Bamias, Aristotelis
    Knox, Jennifer J.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
    Leong, Sally
    Ali, Sana
    Zengin, Zeynep Busra
    Meza, Luis A.
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Govindarajan, Ameish
    Castro, Daniela V.
    Li, Xiaochen
    Kim, Tane
    Melamed, Sam
    Pal, Sumanta Monty
    Chehrazi-Raffle, Alex
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Stukalin, Igor
    Wells, J. Connor
    Fraccon, Anna
    Pasini, Felice
    Porta, Camillo
    Lalani, Aly-Khan A.
    Srinivas, Sandy
    Bowman, I. Alex
    Brugarolas, James
    Lee, Jae-Lyun
    Donskov, Frede
    Beuselinck, Benoit
    Bamias, Aristotelis
    Rini, Brian, I
    Sim, Hao-Wen
    Agarwal, Neeraj
    Rha, Sun-Young
    Kanesvaran, Ravindran
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    [J]. KIDNEY CANCER, 2018, 2 (01) : 31 - 36
  • [8] Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Dudani, Shaan
    de Velasco, Guillermo
    Wells, Connor
    Gan, Chun Loo
    Donskov, Frede
    Porta, Camillo
    Fraccon, Anna
    Pasini, Felice
    Hansen, Aaron Richard
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Pal, Sumanta K.
    Hotte, Sebastien J.
    Lalani, Aly-Khan A.
    Yuasa, Takeshi
    Kanesvaran, Ravindran
    Reaume, M. Neil
    Canil, Christina M.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Stukalin, Igor
    Wells, Connor
    Fraccon, Anna Paola
    Pasini, Felice
    Porta, Camillo
    Moreira, Raphael Brandao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
    Lemelin, A.
    Takemura, K.
    Boyne, D. J.
    Warkentin, M. T.
    Brenner, D. R.
    Cheun, W. Y.
    Wells, J. C.
    Labaki, C.
    McGregor, B. A.
    Basappa, N. S.
    Meza, L. A.
    Pal, S. K.
    Beuselinck, B.
    Mckay, R. R.
    Szabados, B. E.
    Powles, T. B.
    Yuasa, T.
    Ludwig, L.
    Choueiri, T. K.
    Heng, D. Y. C.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1023 - S1024
12345